Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 16 peer-reviewed journal articles Updated
Endocrinology

Managing Hunger and Weight: The Science of Hyperphagia

At a Glance

Hyperphagia in Bardet-Biedl Syndrome is caused by blocked fullness signals in the brain, creating a constant feeling of starvation. Setmelanotide (Imcivree) is an FDA-approved injection that bypasses these blocked signals to reduce insatiable hunger and promote weight loss.

One of the most challenging aspects of Bardet-Biedl Syndrome (BBS) for many patients is hyperphagia—a medical term for an insatiable, overwhelming hunger [1]. This is not a matter of willpower; it is a direct result of the “cellular antenna” problem in the brain [2].

The Starving Brain Paradox

To understand hyperphagia, we have to look at the hypothalamus, the part of the brain that controls hunger and energy [3]. In a typical brain, a hormone called leptin sends a signal saying, “I am full.” This signal travels through a pathway called the MC4R pathway [4].

In BBS, because the BBSome (the cellular delivery truck) is broken, the “I am full” signals cannot reach their destination [5][6]. This creates a paradox: even if the body has stored plenty of energy as fat, the brain remains in a “starvation mode” [5]. This leads to:

  • Constant Hunger: A physical sensation of never being full.
  • Food-Seeking Behaviors: This may include searching for food, hiding food, or becoming extremely distressed when food is not available [1][7].
  • Rapid Weight Gain: Because the body thinks it is starving, it slows down its metabolism and stores every calorie possible [5].

Breakthrough Treatment: Setmelanotide (Imcivree)

Until recently, managing weight in BBS relied solely on strict diets and exercise, which were often unsuccessful because they did not address the underlying hunger [8].

The approval of Setmelanotide (brand name Imcivree) for patients ages 6 and older (including adults) has changed the landscape of BBS care. It is a targeted therapy designed specifically to bypass the “broken” signaling and activate the MC4R pathway directly [9][10].

Proven Benefits

Clinical trials have shown that setmelanotide can significantly change the daily lives of patients:

  • Reduced Hunger: Many patients report a “quieting” of the constant food-seeking thoughts, leading to improved emotional well-being [1][7].
  • Weight Loss: In Phase 3 trials, a significant number of patients achieved a 10% or greater reduction in body weight over one year [9][7].
  • Additional Metabolic Health: Early evidence suggests the medication may also improve liver health and potentially kidney function (eGFR) [11].
  • Cognitive Improvements: Some case reports have even noted improvements in focus and mood after starting treatment [12].

What to Expect During Treatment

Setmelanotide is not a cure, but a long-term management tool. It is currently delivered as a daily injection under the skin [13].

  • Common Side Effects: The most common side effect is hyperpigmentation, where the skin or existing moles may become darker [14][15]. Nausea or injection site reactions can also occur [16].
  • Important Sensitivities: A critical side effect of this specific medication class is the potential for spontaneous penile erections in males and unexpected sexual arousal in females. It is important to be aware of this and discuss it openly with your care team.
  • Support: Starting this treatment often requires a specialized nursing or medical team to help you learn the injection process and monitor your progress [13].

Comprehensive Management

While medication is a powerful tool, it works best as part of a multidisciplinary plan [2]. This includes working with a dietitian who understands BBS and creating a supportive, “food-secure” environment at home where the stress around mealtimes is reduced [1][13].

Common questions in this guide

Why does Bardet-Biedl Syndrome cause constant hunger?
In BBS, cellular delivery issues prevent the brain's hypothalamus from receiving 'fullness' signals. This tricks the brain into thinking the body is starving, leading to an insatiable, overwhelming hunger known as hyperphagia.
What does setmelanotide (Imcivree) do for BBS patients?
Setmelanotide is an FDA-approved daily injection that bypasses the broken cellular signals in BBS to directly activate the pathway controlling hunger. It helps quiet constant food-seeking thoughts and promotes significant weight loss.
What are the common side effects of setmelanotide?
The most common side effect is hyperpigmentation, which causes the skin or existing moles to darken. Other possible side effects include nausea, injection site reactions, and unexpected sexual arousal or spontaneous erections.
Can diet and exercise alone manage BBS weight gain?
Strict diets and exercise are often unsuccessful on their own because they do not fix the underlying broken hunger signals in the brain. Effective management usually requires a combination of targeted medication, a specialized dietitian, and a supportive, food-secure environment.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Am I a candidate for setmelanotide (Imcivree) treatment?
  2. 2.How does setmelanotide specifically address the 'broken signaling' in my brain?
  3. 3.What specific skin changes (hyperpigmentation) should I look for, and when should I consult a dermatologist?
  4. 4.Beyond weight loss, how will we measure if this treatment is improving my metabolic health or cognitive function?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (16)
  1. 1

    Interview-Based Patient- and Caregiver-Reported Experiences of Hunger and Improved Quality of Life with Setmelanotide Treatment in Bardet-Biedl Syndrome.

    Ervin C, Norcross L, Mallya UG, et al.

    Advances in therapy 2023; (40(5)):2394-2411 doi:10.1007/s12325-023-02443-y.

    PMID: 36961653
  2. 2

    Monitoring and Management of Bardet-Biedl Syndrome: What the Multi-Disciplinary Team Can Do.

    Caba L, Florea L, Braha EE, et al.

    Journal of multidisciplinary healthcare 2022; (15()):2153-2167 doi:10.2147/JMDH.S274739.

    PMID: 36193191
  3. 3

    Bardet-Biedl syndrome: A focus on genetics, mechanisms and metabolic dysfunction.

    Tomlinson JW

    Diabetes, obesity & metabolism 2024; (26 Suppl 2()):13-24 doi:10.1111/dom.15480.

    PMID: 38302651
  4. 4

    Effect of setmelanotide, a melanocortin-4 receptor agonist, on obesity in Bardet-Biedl syndrome.

    Haws R, Brady S, Davis E, et al.

    Diabetes, obesity & metabolism 2020; (22(11)):2133-2140 doi:10.1111/dom.14133.

    PMID: 32627316
  5. 5

    Ciliary signaling proteins are mislocalized in the brains of Bardet-Biedl syndrome 1-null mice.

    Stubbs T, Bingman JI, Besse J, Mykytyn K

    Frontiers in cell and developmental biology 2022; (10()):1092161 doi:10.3389/fcell.2022.1092161.

    PMID: 36699005
  6. 6

    Loss of Bardet-Biedl syndrome proteins causes synaptic aberrations in principal neurons.

    Haq N, Schmidt-Hieber C, Sialana FJ, et al.

    PLoS biology 2019; (17(9)):e3000414 doi:10.1371/journal.pbio.3000414.

    PMID: 31479441
  7. 7

    Quality of life improvements following one year of setmelanotide in children and adult patients with Bardet-Biedl syndrome: phase 3 trial results.

    Forsythe E, Haws RM, Argente J, et al.

    Orphanet journal of rare diseases 2023; (18(1)):12 doi:10.1186/s13023-022-02602-4.

    PMID: 36647077
  8. 8

    [Improved Care and Treatment Options for Patients with Hyperphagia-Associated Obesity in Bardet-Biedl Syndrome].

    Cetiner M, Bergmann C, Bettendorf M, et al.

    Klinische Padiatrie 2024; (236(5)):269-279 doi:10.1055/a-2251-5382.

    PMID: 38458231
  9. 9

    Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, in patients with Bardet-Biedl syndrome and Alström syndrome: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial with an open-label period.

    Haqq AM, Chung WK, Dollfus H, et al.

    The lancet. Diabetes & endocrinology 2022; (10(12)):859-868 doi:10.1016/S2213-8587(22)00277-7.

    PMID: 36356613
  10. 10

    Hyperphagia in Bardet-Biedl syndrome: Pathophysiology, burden, and management.

    Beales PL, Cetiner M, Haqq AM, et al.

    Obesity reviews : an official journal of the International Association for the Study of Obesity 2025; (26(7)):e13915 doi:10.1111/obr.13915.

    PMID: 40186386
  11. 11

    Impact of the Melanocortin-4 Receptor Agonist Setmelanotide on MASLD and Kidney Function in Bardet-Biedl Syndrome.

    Hühne T, Polichronidou IM, Finkelberg I, et al.

    The Journal of clinical endocrinology and metabolism 2026; (111(3)):721-733 doi:10.1210/clinem/dgaf483.

    PMID: 40903014
  12. 12

    Case Report: Improvement in cognitive functioning following setmelanotide initiation in a patient with Bardet-Biedl syndrome.

    Kuk M, Richards J, Ross RA

    Frontiers in endocrinology 2025; (16()):1646663 doi:10.3389/fendo.2025.1646663.

    PMID: 41048439
  13. 13

    Patient and caregiver experiences with a patient-support program for setmelanotide treatment of patients with Bardet-Biedl syndrome.

    Finkelberg I, Polichronidou IM, Hühne T, et al.

    Orphanet journal of rare diseases 2025; (20(1)):290 doi:10.1186/s13023-025-03835-9.

    PMID: 40484968
  14. 14

    Efficacy and Safety of Setmelanotide, a Melanocortin-4 Receptor Agonist, for Obese Patients: A Systematic Review and Meta-Analysis.

    Ferraz Barbosa B, Aquino de Moraes FC, Bordignon Barbosa C, et al.

    Journal of personalized medicine 2023; (13(10)) doi:10.3390/jpm13101460.

    PMID: 37888071
  15. 15

    A Melanocortin-4 Receptor Agonist Induces Skin and Hair Pigmentation in Patients with Monogenic Mutations in the Leptin-Melanocortin Pathway.

    Kanti V, Puder L, Jahnke I, et al.

    Skin pharmacology and physiology 2021; (34(6)):307-316 doi:10.1159/000516282.

    PMID: 34058738
  16. 16

    Adverse event profile of setmelanotide in obesity: an integrated assessment and systematic review using disproportionality analysis, case reports and meta-analysis.

    Sridharan K, Sivaramakrishnan G

    Expert opinion on drug safety 2025; 1-10 doi:10.1080/14740338.2025.2465880.

    PMID: 39924461

This page explains hyperphagia and weight management in Bardet-Biedl Syndrome for educational purposes only. Always consult your endocrinologist or care team before making changes to your diet or starting new treatments like setmelanotide.

Get notified when new evidence is published on Bardet-Biedl syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.